Jbog--IMCL has an impressive pipeline. Given the number of clinical trials it seems to me that IMCL will need help in development/clinical trials. How do you think IMCL will proceed with development (go it alone vs collaborations). I know IMCL has mentioned potential collaborations for non-oncology indications. What molecule(s) does it make sense for IMCL to develop without a partner? The questions I have are when will IMCL partner, at what stage phase of development, and with whom. I would think that the anti-IGFR antibody would be a good candidate to partner due to the multiple competing molecules in development. On the other hand IMCL has NCI support in the development of this molecule.
Comments appreciated,
biophud
News 
Market Data 
Discover 
